Only 2 Years of Extended Anastrozole Needed in Breast Cancer Only 2 Years of Extended Anastrozole Needed in Breast Cancer
After an initial 5 years of endocrine therapy in postmenopausal cancer, a further 2 years of the aromatase inhibitor is sufficient, instead of another 5 years, suggest new results.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Health | Hematology